NAD+ vs MOTS-c: What’s the Difference?

What is the difference between NAD+ and MOTS-c?

NAD+ is a coenzyme central to redox and energy metabolism, including reactions governed by NAD-dependent enzymes; it is not a peptide. MOTS-c is a 16-amino-acid peptide arising from a short open reading frame in the mitochondrial 12S rRNA region of mtDNA. NAD+ has well-established biology and multiple human precursor trials with mixed benefit, while MOTS-c evidence is largely preclinical and observational physiology; an ongoing Phase 2a study had no posted results on September 12, 2026. They are not interchangeable.

NAD+: a ubiquitous cellular coenzyme

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in cells. It participates in oxidation–reduction reactions that help transfer electrons during energy metabolism, and it is consumed or used by enzyme families involved in processes such as DNA-damage responses and cellular signaling.

Cells can make NAD+ through several routes, including pathways involving tryptophan and the vitamin B3-related compounds nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The salvage pathway, in which NAMPT is an important enzyme, is one subject of aging research. A measured change in NAD+ in a tissue is not automatically a diagnosis, and a biochemical change after a precursor does not automatically demonstrate a meaningful health outcome. Age, tissue, assay, diet, disease, and study design all matter when interpreting a result. A review of NAD+ metabolism emphasizes this context-dependence.[3]

MOTS-c: a mitochondrial-derived peptide

MOTS-c is not a coenzyme or a vitamin-like precursor. It is a short peptide: the 2015 discovery report described 16 amino acids arising from a short open reading frame within the mitochondrial 12S rRNA region of mtDNA. That origin places it among mitochondrial-derived peptides, a group studied for possible communication between mitochondrial state and the rest of the cell.[1]

Early work proposed links with folate and purine metabolism and AMPK-related metabolic signaling. These mechanisms are useful hypotheses, not a clinical definition of what MOTS-c does in every person. Human circulating measurements are affected by sampling and assay questions, and an association between MOTS-c and a physiological state cannot by itself show that the peptide caused it. The memorable “exercise mimetic” label is a research hypothesis, not a claim that a molecule replaces exercise.

Evidence at a glance

The most useful comparison is not which molecule sounds more powerful. It is what each molecule is, what has actually been measured in people, and how far the evidence has progressed. The table separates human, interventional, and preclinical evidence.

The biology differs before the comparison begins

NAD+ is part of the cell’s chemistry: it cycles between oxidized and reduced forms and interacts with many enzymes. MOTS-c is a signal candidate whose abundance, location, and effects may change with metabolic stress. One is a widely distributed cofactor; the other is a small, mitochondria-encoded message under investigation. Calling both “energy molecules” hides this distinction and encourages conclusions the experiments have not tested.

This difference also changes the evidence questions. For NAD+, researchers can ask whether a precursor changes NAD-related metabolites and whether that change tracks with a measured physiological endpoint. For MOTS-c, researchers must first establish how endogenous peptide levels relate to physiology, how assays compare, and whether an observed signal is causal. A plausible pathway is a starting point for a trial, not the result of one.

What human NAD+ precursor evidence shows

Human NR and NMN research has moved beyond cells and mice, but “more human studies” does not mean “settled clinical benefit.” A review of 25 human NR papers reported that few demonstrated effects that could reasonably be called clinically relevant. Across the literature, biochemical engagement—such as changes in NAD-related measures—has been easier to observe than consistent improvements in meaningful function. This is an important distinction when a surrogate marker is presented as an outcome.[5]

A broader review of NAD+-boosting compounds describes a still varied human literature with many small trials, making comparisons across compounds and endpoints difficult.[6] A 2026 PRISMA-guided review covering 33 human and 80 rodent studies published from 2010 through October 2025 found broadly consistent biochemical engagement with NR or NMN, but heterogeneous functional, metabolic, and vascular findings. Many endpoint-specific results were null, and the review concluded that effectiveness remains inconclusive. The count of trials is therefore not a verdict for every product, person, or outcome; it is a reason to ask what was measured and whether the result matters.[7]

This does not make NAD+ research uninformative. It means the strongest defensible statement is narrower: some NAD+-boosting compounds can alter relevant biochemical measures in humans, while clinical effects vary by compound, population, duration, tissue, and endpoint. Reviews of NAD+ metabolism also caution that aging-related changes are tissue- and method-dependent, so a blood measurement should not be stretched into a universal claim about the body.[3]

What human MOTS-c evidence shows

Human MOTS-c work is mostly endogenous observational or physiology research: investigators measure the peptide in people, often in relation to exercise, metabolic state, or other characteristics. Such studies can identify patterns and generate hypotheses, but they cannot by themselves establish that changing MOTS-c improves an outcome. The sample, assay, timing, tissue context, and population all shape what an association means.

In the 2021 Nature Communications study, Reynolds and colleagues reported an exercise-related increase in endogenous MOTS-c in skeletal muscle and plasma in a small group of healthy young men; they also reported performance-related findings after treatment in mice. The human observation and the mouse intervention answer different questions, so the paper should not be summarized as proof of a human exercise-mimetic effect.[2]

There is now a registered interventional study to watch, but it is not an efficacy result. As verified on September 12, 2026, ClinicalTrials.gov lists NCT07505745 as RECRUITING. Its exact official title is A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity. The record showed no results posted and was last posted April 1, 2026. That is registry status as of the evidence check, not an automatic current-date claim.[8]

What animal and laboratory studies add

The 2015 Lee discovery report described MOTS-c’s short mitochondrial open reading frame and metabolic mouse findings involving insulin resistance and diet-induced obesity. It also proposed connections with AMPK and one-carbon metabolism. These results are valuable for identifying mechanisms worth testing, but a mouse phenotype is not a human clinical outcome.[1]

The NAD+ health and aging review describes preclinical promise that helped motivate human precursor trials while emphasizing translation limits. Animal and laboratory findings can identify mechanisms, but they cannot settle human safety, effective exposure, or whether a laboratory change translates into better health.[4]

Why this is not an apples-to-apples contest

A direct “winner” comparison assumes the molecules have the same job and have been tested against the same outcomes. They have not. NAD+ precursor studies often begin with a measurable biochemical target and then examine selected metabolic, vascular, or functional endpoints. MOTS-c studies more often begin with endogenous physiology or a mechanistic hypothesis, with human intervention evidence still developing. Different starting points produce different kinds of uncertainty.

Even within one category, a precursor, a peptide, and a cellular measurement are not interchangeable interventions. Dose, formulation, route, duration, baseline status, coexisting disease, and assay quality can change an answer. An animal result cannot be used to fill a human evidence gap, and a rise in a biomarker cannot be used to declare a meaningful outcome. A fair comparison is therefore about evidence maturity and question-matching, not marketing language.

What remains uncertain

For NAD+, open questions include which people, tissues, and age-related contexts matter; whether biochemical engagement persists; which outcomes are clinically meaningful; and whether benefits, if present, outweigh harms over longer periods. For MOTS-c, the gaps are more foundational: reproducible measurement, endogenous physiology, causal mechanisms, human safety, and results from appropriately reported intervention studies.

Neither uncertainty list is an argument for a particular personal choice. It is an argument for reading the denominator and endpoint before reading the headline. Ask whether the evidence is observational, physiological, interventional, animal, or cellular; whether the comparator is credible; whether the sample is large enough for the claim; and whether the result was actually posted. A careful answer can be useful without becoming a dosing, injection, protocol, treatment, or sourcing recommendation.

The most accurate bottom line today is modest: NAD+ has a more developed human precursor literature with inconsistent clinical implications, while MOTS-c is a promising but earlier-stage mitochondrial peptide research topic. “More developed” is not the same as “proven,” and “promising” is not the same as “effective.”

Five questions readers often ask

Read the evidence in context

For a fuller, source-led comparison, see NAD+ vs MOTS-c: The Honest Comparison. The book follows the molecules from basic biology through human, animal, and laboratory evidence without turning an unresolved research question into a personal protocol.

Related reading: NAD+ and aging · MOTS-c and exercise · all articles